StepanSCL
SCL logo
Fair Value
US$85
Share price07 Aug
US$62.1626.9% undervalued intrinsic discount
Loading
1Y22.97%
7D-3.96%

Pasadena Site And Tech Integration Will Unlock Future Opportunities

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
24 Sep 24
Updated
07 Aug 26
Views
244
Not Invested

Last Update 07 Aug 26

Fair value Increased 13%

SCL: Higher Margin Assumptions Will Support Long-Term Dividend Upside

Analysts have raised their price target for Stepan from $75 to $85, citing updated assumptions that include a lower discount rate, an increased profit margin of 10.80%, and a more conservative future P/E of 8.05x.

What’s in the News for Stepan

  • Stepan Company was added to the Russell 2000 Dynamic Index as an index constituent. Source: Key Developments.

Valuation Changes for Stepan

  • Fair Value has been raised from $75 to $85. This represents a moderate upward adjustment to the estimated value for Stepan.
  • Discount Rate has been reduced slightly from 8.20% to 7.95%. This indicates a marginally lower required rate of return in the updated model.
  • Revenue Growth assumptions have eased slightly from 5.68% to 5.16%. This reflects a more restrained outlook for Stepan's top line expansion assumptions.
  • Net Profit Margin has moved sharply higher from 4.98% to 10.80%. The updated model now incorporates a much stronger level of profitability for Stepan.
  • Future P/E has been cut from 15.86x to 8.05x. The valuation framework now applies a more conservative earnings multiple for Stepan.
5 viewsusers have viewed this narrative update

Key Takeaways

  • Growth in specialty alkoxylation and strategic end markets indicates potential for continued revenue and earnings increases across key segments.
  • The startup of the new Texas site and focus on acquiring over 400 new customers can boost volume growth and supply chain savings.
  • Global macroeconomic uncertainties and competitive pressures could negatively impact revenue, margins, and cash flow across multiple segments for Stepan.

Catalysts

About Stepan
    Produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products worldwide.
What are the underlying business or industry changes driving this perspective?
  • The startup of the new Pasadena, Texas site is expected to reach full contribution in the second half of 2025, which could boost volume growth and supply chain savings. This is likely to impact revenue and margins positively.
  • Strong growth in specialty alkoxylation, showing 19% growth in Q1, suggests continued revenue growth and earnings improvement in the Surfactants business with enhanced customer and product mix.
  • The broad-based volume growth in key strategic end markets, including double-digit growth in agricultural and oilfield sectors, indicates potential for continued revenue and earnings growth across these segments.
  • The strategic focus on new customer acquisition, especially with over 400 new customers in tier 2 and tier 3, should drive revenue growth and improve net margins due to a more diversified and high-value customer base.
  • The successful integration of new technologies and products in the insulation and spray foam markets in the Polymers segment suggests potential for future revenue growth and improved margins as these markets expand.
Stepan Earnings and Revenue Growth

Stepan Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Stepan's revenue will grow by 5.2% annually over the next 3 years.
  • Analysts assume that profit margins will increase from -0.1% today to 10.8% in 3 years time.
  • Analysts expect earnings to reach $305.5 million (and earnings per share of $13.29) by about August 2029, up from -$2.7 million today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 8.3x on those 2029 earnings, up from -547.8x today. This future PE is lower than the current PE for the US Chemicals industry at 28.5x.
  • Analysts expect the number of shares outstanding to grow by 1.24% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.95%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • The high interest rate environment and global macroeconomic uncertainties are restraining Rigid Polyol growth in North America and Europe, potentially impacting revenues and net margins.
  • Negative free cash flow of $25.8 million due to high working capital requirements and increased raw material purchases could pressure financials such as cash flow and net earnings if not addressed.
  • The Surfactants segment faces risks from raw material cost increases that are passed through to selling prices; any inability to effectively manage these costs could compress profit margins.
  • Competitive pressures and a decline in selling prices in the Polymers segment, despite volume growth, could lead to lower overall revenue and operating income.
  • Tariffs and trade uncertainties may create inflationary pressures and indirect impacts on consumer demand, which could result in decreased sales volumes and negatively affect earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $85.0 for Stepan based on their expectations of its future earnings growth, profit margins and other risk factors.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $2.8 billion, earnings will come to $305.5 million, and it would be trading on a PE ratio of 8.3x, assuming you use a discount rate of 7.9%.
  • Given the current share price of $63.96, the analyst price target of $85.0 is 24.8% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Stepan?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$85
vs US$62.1626.9% undervalued intrinsic discount
PastFuture03b2015201820212024202620272029Revenue US$2.8bEarnings US$305.5m
5.2%
Revenue growth
10.8%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Stepan

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Undervalued with adequate balance sheet.

Market capUS$1.4b
PB1.2x
Estimated Growth4.6%
Dividend Yield2.5%
Full analysis

CEO & management

Luis Rojo
CEO
2.5yrs
CEO Tenure

Produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products in the United States, France, Poland, the United Kingdom, Brazil, Mexico, and internationally.